Activity values for VWF and FVIII in heterozygous VWD and normal dogs treated with either rhIL-11 or DDAVP
. | rhIL-11 . | . | . | . | DDAVP . | . | . | . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Heterozygous VWD . | . | Normal* . | . | Heterozygous VWD . | . | Normal* . | . | ||||||
. | VWF . | FVIII . | VWF . | FVIII . | VWF . | FVIII . | VWF . | FVIII . | ||||||
Baseline | 100 (34) | 100 (69) | 100 (61) | 100 (39) | 100 (46) | 100 (77) | 100 (85) | 100 (45) | ||||||
Day 1 | 146 (50) | 144 (99) | 121 (74) | 92 (36) | 160 (73) | 162 (125) | 239 (203) | 172 (78) | ||||||
Day 5 | 244 (83) | 138 (95) | 261 (159) | 163 (64) | 204 (93) | 167 (129) | 146 (125) | 126 (57) | ||||||
Day 7 | 294 (100) | 178 (123) | 320 (194) | 244 (95) | 126 (57) | 131 (101) | 125 (107) | 104 (47) | ||||||
Day 14 | 134 (48) | 100 (69) | 94 (57) | 98 (38) | 117 (54) | 190 (147) | 110 (93) | 104 (47) |
. | rhIL-11 . | . | . | . | DDAVP . | . | . | . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Heterozygous VWD . | . | Normal* . | . | Heterozygous VWD . | . | Normal* . | . | ||||||
. | VWF . | FVIII . | VWF . | FVIII . | VWF . | FVIII . | VWF . | FVIII . | ||||||
Baseline | 100 (34) | 100 (69) | 100 (61) | 100 (39) | 100 (46) | 100 (77) | 100 (85) | 100 (45) | ||||||
Day 1 | 146 (50) | 144 (99) | 121 (74) | 92 (36) | 160 (73) | 162 (125) | 239 (203) | 172 (78) | ||||||
Day 5 | 244 (83) | 138 (95) | 261 (159) | 163 (64) | 204 (93) | 167 (129) | 146 (125) | 126 (57) | ||||||
Day 7 | 294 (100) | 178 (123) | 320 (194) | 244 (95) | 126 (57) | 131 (101) | 125 (107) | 104 (47) | ||||||
Day 14 | 134 (48) | 100 (69) | 94 (57) | 98 (38) | 117 (54) | 190 (147) | 110 (93) | 104 (47) |
VWF activity by botrocetin-based bioassay and FVIII activity by Coamatic are reported as percentage of baseline. Actual values are shown in parentheses. Measurements were made at 30 minutes after treatment on days 1, 5, and 7 and at a comparable time on day 14.
Average of 2 normal dogs.